2. Gene
  3. Bcr - BCR activator of RhoGEF and GTPase Gene

Bcr - BCR activator of RhoGEF and GTPase Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

种属: Mus musculus

同用名: mKIAA3017; 5133400C09Rik

基因 ID: 110279 | 基因类型: protein coding

关于 Bcr

功能概要

Enables GTPase activator activity. Involved in several processes, including negative regulation of blood vessel remodeling; negative regulation of cellular extravasation; and regulation of vascular permeability. Acts upstream of or within several processes, including animal organ development; cellular response to lipopolysaccharide; and regulation of vesicle-mediated transport. Located in cytosol; plasma membrane; and postsynaptic density. Is active in Schaffer collateral - CA1 synapse and glutamatergic synapse. Is expressed in several structures, including cardiovascular system; central nervous system; forelimb bud; genitourinary system; and spleen. Human ortholog(s) of this gene implicated in acute lymphoblastic leukemia; chronic myeloid leukemia; and leukemia. Orthologous to human BCR (BCR activator of RhoGEF and GTPase). [provided by Alliance of Genome Resources, Apr 2022]

Bcr 基因产物(1)

mRNA Protein Name
NM_001081412.2 NP_001074881.1 breakpoint cluster region protein
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables GTPase activator activity IDA
IDA: 通过直接分析推断
17116687 MGI
enables GTPase activator activity IGI
IGI: 通过遗传相互作用推断
19703997 MGI
enables protein binding IPI
IPI: 通过物理相互作用推断
17000758 MGI
生物过程 GO 注释 逻辑证据 参考文献 来源
acts upstream of or within actin cytoskeleton organization IGI
IGI: 通过遗传相互作用推断
17116687 MGI
acts upstream of or within brain development IGI
IGI: 通过遗传相互作用推断
11684658 MGI
acts upstream of cell migration IGI
IGI: 通过遗传相互作用推断
17116687 MGI
acts upstream of or within cellular response to lipopolysaccharide IMP
IMP: 通过突变表型推断
7889565 MGI
acts upstream of or within definitive hemopoiesis IMP
IMP: 通过突变表型推断
7889565 MGI
acts upstream of establishment of localization in cell IGI
IGI: 通过遗传相互作用推断
17116687 MGI
acts upstream of or within homeostasis of number of cells IMP
IMP: 通过突变表型推断
7889565 MGI
acts upstream of or within inner ear morphogenesis IGI
IGI: 通过遗传相互作用推断
11921339 MGI
acts upstream of or within intracellular protein transmembrane transport IMP
IMP: 通过突变表型推断
7889565 MGI
acts upstream of macrophage migration IGI
IGI: 通过遗传相互作用推断
17116687 MGI
involved in modulation of chemical synaptic transmission IDA
IDA: 通过直接分析推断
20962234 MGI
involved in modulation of chemical synaptic transmission IMP
IMP: 通过突变表型推断
20962234 MGI
involved in negative regulation of blood vessel remodeling IMP
IMP: 通过突变表型推断
23152932 MGI
involved in negative regulation of cellular extravasation IMP
IMP: 通过突变表型推断
23152932 MGI
acts upstream of or within negative regulation of inflammatory response IMP
IMP: 通过突变表型推断
19703997 MGI
acts upstream of or within negative regulation of macrophage migration IGI
IGI: 通过遗传相互作用推断
17116687 MGI
acts upstream of or within negative regulation of neutrophil degranulation IGI
IGI: 通过遗传相互作用推断
19703997 MGI
acts upstream of or within negative regulation of reactive oxygen species metabolic process IMP
IMP: 通过突变表型推断
7889565 MGI
acts upstream of or within negative regulation of respiratory burst IMP
IMP: 通过突变表型推断
7889565 MGI
acts upstream of or within neuromuscular process controlling balance IGI
IGI: 通过遗传相互作用推断
11921339 MGI
acts upstream of neutrophil degranulation IGI
IGI: 通过遗传相互作用推断
19703997 MGI
acts upstream of phagocytosis IGI
IGI: 通过遗传相互作用推断
17116687 MGI
acts upstream of or within positive regulation of phagocytosis IGI
IGI: 通过遗传相互作用推断
17116687 MGI
acts upstream of or within regulation of cell cycle IDA
IDA: 通过直接分析推断
11809706 MGI
involved in regulation of vascular permeability IMP
IMP: 通过突变表型推断
23152932 MGI
acts upstream of or within renal system process IMP
IMP: 通过突变表型推断
7889565 MGI
acts upstream of or within response to lipopolysaccharide IMP
IMP: 通过突变表型推断
19703997 MGI
细胞组分 GO 注释 逻辑证据 参考文献 来源
is active in Schaffer collateral - CA1 synapse IDA
IDA: 通过直接分析推断
20962234 MGI
is active in Schaffer collateral - CA1 synapse IMP
IMP: 通过突变表型推断
20962234 MGI
located in cytosol IDA
IDA: 通过直接分析推断
17116687 MGI
is active in glutamatergic synapse IDA
IDA: 通过直接分析推断
20962234 MGI
is active in glutamatergic synapse IMP
IMP: 通过突变表型推断
20962234 MGI
located in plasma membrane IDA
IDA: 通过直接分析推断
17116687 MGI
located in postsynaptic density IDA
IDA: 通过直接分析推断
25331951 MGI
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断
蛋白主名 其他名称

breakpoint cluster region protein

breakpoint cluster region homolog

相关产品

Approval
生物活性分子 (17)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10181 Dasatinib 99.85% 是
HY-15463 Imatinib 99.95% 是
HY-10159 Nilotinib 99.94% 是
HY-50946 Imatinib Mesylate 99.98% 是
HY-104010 Asciminib Inhibitor 99.61% 是
HY-15666 Olverembatinib Inhibitor 99.65% 是
HY-10181A Dasatinib hydrochloride 99.67% 是
HY-129390 Orelabrutinib Inhibitor 99.97% 是
HY-10159A Nilotinib monohydrochloride monohydrate 99.91% 是
HY-13904 Flumatinib Inhibitor 99.94% 否
HY-15728 Radotinib 99.19% 是
HY-104010A Asciminib hydrochloride Inhibitor 99.84% 是
HY-10181B Dasatinib monohydrate 99.58% 是
HY-15666A Olverembatinib dimesylate Inhibitor 99.80% 是
HY-13905 Flumatinib mesylate Inhibitor 99.80% 否
HY-10159B Nilotinib hydrochloride / 否
HY-50946R Imatinib Mesylate (Standard) / 否
Clinical Phase
生物活性分子 (9)
目录号 产品名 作用方式
纯度 Phase
HY-13024 Rebastinib 99.91% Phase 2
HY-50868 Bafetinib 99.18% Phase 2
HY-137460 Vodobatinib Inhibitor 98.09% Phase 2
HY-109010 Poseltinib Inhibitor 98.08% Phase 2
HY-109082 Cevidoplenib Inhibitor 99.58% Phase 2
HY-120508 Pivanex ≥95.0% Phase 2
HY-15493 AN-019 Inhibitor / Phase 2
HY-15749 XL228 Inhibitor 99.64% Phase 1
HY-118084 LS-104 / Phase 1
抗体抑制剂 (2)
目录号 产品名 作用方式
纯度 Phase
HY-P99761 Obexelimab ≥99.0% Phase 3
HY-P991086 MGD010 Inhibitor / Phase 2
Pre-clinical Phase
生物活性分子 (112)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-13520 Nocodazole 99.59% 否
HY-130604 DT2216 99.97% 否
HY-13264 Degrasyn 99.70% 否
HY-147308 Zelenirstat Inhibitor 99.05% 否
HY-125845 (S,R,S)-AHPC 99.13% 否
HY-11007 GNF-2 Inhibitor 99.82% 否
HY-15738 GNF-5 Inhibitor 99.95% 否
HY-125834 GMB-475 98.69% 否
HY-152036A SIAIS100 TFA Degrader 99.46% 否
HY-10943 GNF-7 Inhibitor 99.70% 否
HY-158145 DS55980254 Inhibitor 99.65% 否
HY-128756 SIAIS178 Inhibitor 99.36% 否
HY-157562 DS68591889 99.18% 否
HY-13943 CNX-774 Inhibitor 99.92% 否
HY-103274 PD180970 99.27% 否
HY-153415 PROTAC BCR-ABL Degrader-1 Degrader 98.09% 否
HY-18010 PCI 29732 Inhibitor 99.86% 否
HY-136268 AQX-435 Activator 99.15% 否
HY-153357 NRX-0492 Degrader 98.16% 否
HY-147414 Vamotinib Inhibitor 98.69% 否
HY-10181S Dasatinib-d8 98.20% 否
HY-131669 Dasatinib metabolite M6 99.64% 否
HY-100338 CNX-500 Inhibitor 99.88% 否
HY-107447 N-Deshydroxyethyl Dasatinib 98.58% 否
HY-15463S Imatinib-d8 99.85% 否
HY-10159S Nilotinib-d6 99.95% 否
HY-103032 Multi-kinase inhibitor 1 Inhibitor 99.34% 否
HY-103275 Adaphostin 99.02% 否
HY-15814 HG-7-85-01 99.94% 否
HY-157327 AKE-72 Inhibitor 98.29% 否
HY-123450 S116836 99.60% 否
HY-15463S1 Imatinib-d4 99.97% 否
HY-156148 BCR-ABL-IN-8 Inhibitor / 否
HY-101489A GZD856 (formic) 95.36% 否
HY-117718 AG957 Inhibitor 99.30% 否
HY-123159 AKI603 Inhibitor 98.03% 否
HY-145887 BCR-ABL1-IN-1 99.82% 否
HY-153008 BCR-ABL-IN-7 Inhibitor 99.66% 否
HY-111872 SNIPER(ABL)-020 Inhibitor 99.79% 否
HY-108486 Herbimycin A Inhibitor 99% 否
HY-123390 DB07107 Inhibitor / 否
HY-130297 PROTAC BCR-ABL1 ligand 1 Inhibitor 99.17% 否
HY-133794 Dasatinib N-oxide 99.24% 否
HY-13904S Flumatinib-d3 Inhibitor 98.44% 否
HY-15463S2 Imatinib-d3 hydrochloride 95.19% 否
HY-10159C Nilotinib hydrochloride dihydrate 99.89% 否
HY-41940 Dasatinib intermediate-1 Control / 否
HY-108704 CT-721 Inhibitor / 否
HY-128607 Mcl1-IN-9 Inhibitor / 否
HY-136526 BCR-ABL-IN-3 Inhibitor / 否
HY-152036 SIAIS100 Degrader / 否
HY-133794S Dasatinib N-oxide-d8 / 否
HY-101268 CHMFL-ABL-053 Inhibitor / 否
HY-10159S1 Nilotinib-13C,d3 / 否
HY-101763B (S,R,S)-AHPC dihydrochloride / 否
HY-10181G Dasatinib (GMP) / 否
HY-119177 PD173956 Inhibitor / 否
HY-120036 Tyrphostin AG1112 Inhibitor / 否
HY-131275 Imatinib Impurity E 96.05% 否
HY-142922 BCR-ABL-IN-4 Inhibitor / 否
HY-147581 BTK-IN-11 Inhibitor / 否
HY-147584 BTK-IN-14 Inhibitor / 否
HY-150566 BCR-ABL-IN-5 Inhibitor / 否
HY-150569 BCR-ABL-IN-6 Inhibitor / 否
HY-150908 Brigatinib A / 否
HY-153085 CD19 CAR circRNA / 否
HY-153234 CD19 car circRNA-LNP / 否
HY-153582 ML 2-23 Degrader / 否
HY-15728S Radotinib-d6 / 否
HY-157389 AK-HW-90 Inhibitor / 否
HY-160478 GNF-6 Inhibitor / 否
HY-161323 FLT3-ITD/D835Y-IN-1 / 否
HY-161445 (S,R,S)-AHPC-Me-piperazine-acetyl-PIP-AcOH / 否
HY-162257 BTK-IN-34 Inhibitor / 否
HY-162489 Tyrosine kinase-IN-8 Inhibitor / 否
HY-162698 JMF4073 Inhibitor / 否
HY-162952 cSRC/BCR-ABL1-IN-1 Inhibitor / 否
HY-168963 PROTAC BTK Degrader-13 / 否
HY-169230 BCR-ABL-IN-9 Inhibitor / 否
HY-169231 BCR-ABL-IN-10 Inhibitor / 否
HY-171184 EAPB0503 / 否
HY-172096 cSRC/BCR-ABL-IN-1 Inhibitor / 否
HY-176269 VS1150 / 否
HY-RS01450 BCR Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-10181S1 Dasatinib-d4 / 否
HY-123486 HS-438 / 否
HY-125090 PHA-680626 / 否
HY-132549S Nilotinib-d3 / 否
HY-15463S3 Imatinib-13C,d3 / 否
HY-160174 BCR-ABL kinase-IN-3 Inhibitor / 否
HY-160174A BCR-ABL kinase-IN-3 (dihydrocholide) Inhibitor / 否
HY-164393 ON044580 / 否
HY-164469 CHMFL-48 Inhibitor / 否
HY-169608 BCR-ABL-IN-11 Inhibitor / 否
HY-RS16598 Bcr Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS23032 Bcr Rat Pre-designed siRNA Set A Pre-designed Set / 否
HY-101489 GZD856 / 否
HY-110402 (S,R,S)-AHPC TFA / 否
HY-111871 SNIPER(ABL)-033 Inhibitor / 否
HY-111851 SNIPER(ABL)-049 Inhibitor / 否
HY-111854 SNIPER(ABL)-015 Inhibitor / 否
HY-111858 SNIPER(ABL)-050 Inhibitor / 否
HY-111859 SNIPER(ABL)-058 Inhibitor / 否
HY-111860 SNIPER(ABL)-013 Inhibitor / 否
HY-111861 SNIPER(ABL)-024 Inhibitor / 否
HY-111862 SNIPER(ABL)-044 Inhibitor / 否
HY-111873 SNIPER(ABL)-019 Inhibitor / 否
HY-100314 BCR-ABL-IN-1 Inhibitor / 否
HY-111863 SNIPER(ABL)-047 Inhibitor / 否
HY-111874 SNIPER(ABL)-039 Inhibitor / 否
HY-126143 CHMFL-ABL-039 Inhibitor / 否
HY-18819 BCR-ABL-IN-2 Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Bcr NCBI NCBI:613
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z